Cargando…
The Apolipoprotein A-I Mimetic L-4F Attenuates Monocyte Activation and Adverse Cardiac Remodeling after Myocardial Infarction
Excessive inflammation after myocardial infarction (MI) can promote infarct expansion and adverse left ventricular (LV) remodeling. L-4F, a mimetic peptide of apolipoprotein A-I (apoA-I), exhibits anti-inflammatory and anti-atherogenic properties; however, whether L-4F imparts beneficial effects aft...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279031/ https://www.ncbi.nlm.nih.gov/pubmed/32429244 http://dx.doi.org/10.3390/ijms21103519 |
_version_ | 1783543469062488064 |
---|---|
author | Hamid, Tariq Ismahil, Mohamed Ameen Bansal, Shyam S. Patel, Bindiya Goel, Mehak White, C. Roger Anantharamaiah, G. M. Prabhu, Sumanth D. |
author_facet | Hamid, Tariq Ismahil, Mohamed Ameen Bansal, Shyam S. Patel, Bindiya Goel, Mehak White, C. Roger Anantharamaiah, G. M. Prabhu, Sumanth D. |
author_sort | Hamid, Tariq |
collection | PubMed |
description | Excessive inflammation after myocardial infarction (MI) can promote infarct expansion and adverse left ventricular (LV) remodeling. L-4F, a mimetic peptide of apolipoprotein A-I (apoA-I), exhibits anti-inflammatory and anti-atherogenic properties; however, whether L-4F imparts beneficial effects after myocardial infarction (MI) is unknown. Here we demonstrate that L-4F suppresses the expansion of blood, splenic, and myocardial pro-inflammatory monocytes and macrophages in a mouse model of reperfused MI. Changes in immune cell profiles were accompanied by alleviation of post-MI LV remodeling and dysfunction. In vitro, L-4F also inhibited pro-inflammatory and glycolytic gene expression in macrophages. In summary, L-4F treatment prevents prolonged and excessive inflammation after MI, in part through modulation of pro-inflammatory monocytes and macrophages, and improves post-MI LV remodeling. These data suggest that L-4F could be a used as a therapeutic adjunct in humans with MI to limit inflammation and alleviate the progression to heart failure. |
format | Online Article Text |
id | pubmed-7279031 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72790312020-06-15 The Apolipoprotein A-I Mimetic L-4F Attenuates Monocyte Activation and Adverse Cardiac Remodeling after Myocardial Infarction Hamid, Tariq Ismahil, Mohamed Ameen Bansal, Shyam S. Patel, Bindiya Goel, Mehak White, C. Roger Anantharamaiah, G. M. Prabhu, Sumanth D. Int J Mol Sci Article Excessive inflammation after myocardial infarction (MI) can promote infarct expansion and adverse left ventricular (LV) remodeling. L-4F, a mimetic peptide of apolipoprotein A-I (apoA-I), exhibits anti-inflammatory and anti-atherogenic properties; however, whether L-4F imparts beneficial effects after myocardial infarction (MI) is unknown. Here we demonstrate that L-4F suppresses the expansion of blood, splenic, and myocardial pro-inflammatory monocytes and macrophages in a mouse model of reperfused MI. Changes in immune cell profiles were accompanied by alleviation of post-MI LV remodeling and dysfunction. In vitro, L-4F also inhibited pro-inflammatory and glycolytic gene expression in macrophages. In summary, L-4F treatment prevents prolonged and excessive inflammation after MI, in part through modulation of pro-inflammatory monocytes and macrophages, and improves post-MI LV remodeling. These data suggest that L-4F could be a used as a therapeutic adjunct in humans with MI to limit inflammation and alleviate the progression to heart failure. MDPI 2020-05-15 /pmc/articles/PMC7279031/ /pubmed/32429244 http://dx.doi.org/10.3390/ijms21103519 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hamid, Tariq Ismahil, Mohamed Ameen Bansal, Shyam S. Patel, Bindiya Goel, Mehak White, C. Roger Anantharamaiah, G. M. Prabhu, Sumanth D. The Apolipoprotein A-I Mimetic L-4F Attenuates Monocyte Activation and Adverse Cardiac Remodeling after Myocardial Infarction |
title | The Apolipoprotein A-I Mimetic L-4F Attenuates Monocyte Activation and Adverse Cardiac Remodeling after Myocardial Infarction |
title_full | The Apolipoprotein A-I Mimetic L-4F Attenuates Monocyte Activation and Adverse Cardiac Remodeling after Myocardial Infarction |
title_fullStr | The Apolipoprotein A-I Mimetic L-4F Attenuates Monocyte Activation and Adverse Cardiac Remodeling after Myocardial Infarction |
title_full_unstemmed | The Apolipoprotein A-I Mimetic L-4F Attenuates Monocyte Activation and Adverse Cardiac Remodeling after Myocardial Infarction |
title_short | The Apolipoprotein A-I Mimetic L-4F Attenuates Monocyte Activation and Adverse Cardiac Remodeling after Myocardial Infarction |
title_sort | apolipoprotein a-i mimetic l-4f attenuates monocyte activation and adverse cardiac remodeling after myocardial infarction |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279031/ https://www.ncbi.nlm.nih.gov/pubmed/32429244 http://dx.doi.org/10.3390/ijms21103519 |
work_keys_str_mv | AT hamidtariq theapolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction AT ismahilmohamedameen theapolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction AT bansalshyams theapolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction AT patelbindiya theapolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction AT goelmehak theapolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction AT whitecroger theapolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction AT anantharamaiahgm theapolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction AT prabhusumanthd theapolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction AT hamidtariq apolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction AT ismahilmohamedameen apolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction AT bansalshyams apolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction AT patelbindiya apolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction AT goelmehak apolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction AT whitecroger apolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction AT anantharamaiahgm apolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction AT prabhusumanthd apolipoproteinaimimeticl4fattenuatesmonocyteactivationandadversecardiacremodelingaftermyocardialinfarction |